KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Esperion Therapeutics (ESPR) Equity Ratio: 2018-2024

Historic Equity Ratio for Esperion Therapeutics (ESPR) over the last 7 years, with Dec 2024 value amounting to -1.13.

  • Esperion Therapeutics' Equity Ratio fell 5.21% to -1.24 in Q3 2025 from the same period last year, while for Sep 2025 it was -1.24, marking a year-over-year decrease of 5.21%. This contributed to the annual value of -1.13 for FY2024, which is 48.86% up from last year.
  • Per Esperion Therapeutics' latest filing, its Equity Ratio stood at -1.13 for FY2024, which was up 48.86% from -2.21 recorded in FY2023.
  • In the past 5 years, Esperion Therapeutics' Equity Ratio ranged from a high of -0.27 in FY2020 and a low of -2.21 during FY2023.
  • For the 3-year period, Esperion Therapeutics' Equity Ratio averaged around -1.55, with its median value being -1.31 (2022).
  • Per our database at Business Quant, Esperion Therapeutics' Equity Ratio tumbled by 392.52% in 2020 and then soared by 48.86% in 2024.
  • Esperion Therapeutics' Equity Ratio (Yearly) stood at -0.27 in 2020, then tumbled by 89.65% to -0.52 in 2021, then plummeted by 153.02% to -1.31 in 2022, then plummeted by 69.30% to -2.21 in 2023, then spiked by 48.86% to -1.13 in 2024.